Merck | MRK - Gewinn Vor Steuern

Aktienkurs
113.84
Täglich Wechseln
-0.36 -0.32%
Monatlich
-6.89%
Jährlich
20.17%
Q1 Prognose
112.12




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 4.38B 1.92B 2025-09
Abbott USD 2.36B 178M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 3.24B 117M 2025-09
Biogen USD 557.3M 186.7M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Drreddys Laboratories INR 15.43B 1.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
J&J USD 4.97B 2.53B 2025-12
Medtronic USD 2.1B 224M 2025-09
Merck USD 6.74B 22M 2025-09
Novartis USD 4.64B 445M 2025-12
Novartis USD 5.17B 637M 2025-09
Novo Nordisk DKK 33.8B 3.23B 2025-06
Pacira USD 9.52M 11.45M 2025-09
Perrigo USD 22.4M 19.2M 2025-09
Pfizer USD 3.33B 290M 2025-09
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 69.13M 7.35M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
United Therapeutics USD 444M 6M 2025-12
Zoetis USD 887M 15M 2025-09